Starting November 9, prices for several generic anti-cancer drugs will see significant reductions, providing financial relief for many. Some generics will experience over a 10-fold price cut. However, top-selling patented treatments will not see any price change following the NPPA's revision. Meanwhile, the Supreme Court is considering petitions to regulate high trade margins charged by hospitals. For detailed information, refer to the official publication.
Read the original article